CRISPR Therapeutics and Vertex received approval from the UK's MHRA for the initial gene-edited treatment, CASGEVY™ (exagamglogene autotemcel), targeting Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia employing CRISPR/Cas9 technology.

The 2023 SITC Congress reported that TILT-123, a T-cell inducing oncolytic virus, is safe, effective at fighting tumors, and can boost immune responses in patients with advanced solid tumors.

Carmot Therapeutics has initiated a phase 2 clinical study on CT-868, a unique dual GLP-1/GIP receptor agonist, to treat Type 1 Diabetes.

The first immune checkpoint inhibitor for clinical use: CTLA-4 inhibitor. However, it enhances immune function, specifically by boosting the cytotoxicity of immune cells, which often results in more adverse effects.

A plasmid is a small, circular, double-stranded DNA molecule that is distinct from a cell's chromosomal DNA.

The latest clinical result of SNS-101(Sensei Biotherapeutics) in patients with advanced solid tumors was reported at the 2023 SITC Congress, demenstrating its potential efficacy and paving the way for future research.

Repare Therapeutics introduces two initiatives set to commence clinical testing by 2024: oral PLK4 inhibitor RP-1664, and oral Polθ inhibitor RP-3467.

COX-2 inhibitors aid in the release of prostaglandins, which are synthesized from arachidonic acid. Prostaglandins play a key role in inflammatory responses.

Open reading frame (ORF), in the context of genomics, refers to a section of a DNA sequence that lacks a stop codon and potentially codes for a protein.

This article summarized the latest R&D progress of Umeclidinium Bromide, the Mechanism of Action for Umeclidinium Bromide, and the drug target R&D trends for Umeclidinium Bromide.

Alvotech, a global biotech firm specializing in biosimilar drugs, and Canada's JAMP Pharma have announced Health Canada's approval for AVT04, a Stelara® biosimilar. It will be marketed as Jamteki™.

The 2023 SITC Congress kicked off with a groundbreaking report on the latest clinical results of ENB-003, establishing a solid foundation for future research.